Subtype
Lung Small Cell Carcinoma
CI-CAN-00005832SCLCExplore in graph →
381 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005832SCLCExplore in graph →
Clinical trials
1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (157)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00276276 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | completed | Phase 3 | 141 | GlaxoSmithKlineINDUSTRY | 6 | Apr 15, 2013 | clinicaltrials |
| NCT00951613 | A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 72 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00028028 |
| CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
| completed |
| Phase 2 |
| 80 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Feb 28, 2013 |
| clinicaltrials |
| NCT00017251 | Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00042978 | Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00294190 | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer | completed | Phase 2 | 38 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2012 | clinicaltrials |
| NCT00065429 | Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 64 | ImmunoGen, Inc.INDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00698516 | Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer | completed | Phase 2 | 50 | GlaxoSmithKlineINDUSTRY | 1 | Mar 27, 2012 | clinicaltrials |
| NCT00046787 | Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer | completed | Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 2 | Oct 20, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00317200 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | completed | Phase 2 | 34 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT00403403 | A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Apr 29, 2011 | clinicaltrials |
| NCT00156286 | Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC | completed | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 16, 2010 | clinicaltrials |
| NCT01222936 | LBH Phase II in Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 21 | Southern Europe New Drug OrganizationOTHER | 2 | Oct 18, 2010 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
| NCT00294931 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00308529 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 55 | SCRI Development Innovations, LLCOTHER | 1 | Jun 22, 2010 | clinicaltrials |
| NCT00037713 | Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG | completed | Phase 3 | 515 | Eli Lilly and CompanyINDUSTRY | 0 | Apr 8, 2010 | clinicaltrials |
| NCT00143455 | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer | completed | Phase 3 | 485 | PfizerINDUSTRY | 13 | Feb 18, 2010 | clinicaltrials |
| NCT00363415 | Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 908 | Eli Lilly and CompanyINDUSTRY | 26 | Oct 28, 2009 | clinicaltrials |
| NCT00319969 | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | completed | Phase 2 | 76 | Celgene CorporationINDUSTRY | 1 | Sep 30, 2009 | clinicaltrials |
| NCT00572923 | Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans(BRONC 45 15) | completed | — | 52 | Maastricht Radiation OncologyOTHER | 1 | Jun 17, 2009 | clinicaltrials |
| NCT00252889 | Doxil Topotecan Doublet Cancer Study | completed | Phase 1 | 20 | Christiana Care Health ServicesOTHER | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00116610 | Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | completed | Phase 2 | 75 | Poniard PharmaceuticalsINDUSTRY | 3 | Jan 21, 2009 | clinicaltrials |
| NCT00290953 | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide(SESAME) | completed | Phase 2 / Phase 3 | 432 | SanofiINDUSTRY | 14 | Dec 23, 2008 | clinicaltrials |
| NCT00298688 | A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer | completed | Phase 2 | 56 | AstraZenecaINDUSTRY | 2 | Jun 12, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2013source: clinicaltrials